Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Biodel Inc. ( BIOD ) said its ultra-rapid-acting insulin drug formulations showed positive results in a Phase 1 study compared with Eli Lilly & Co.'s ( LLY ) rapid-acting Humalog insulin treatment.
The biopharmaceutical drug developer's shares were up 26% at $2.96 in early trading.
Biodel, which focuses on diabetes treatments, applies its technology to existing drugs in an effort to improve them. The company's two product formulations--BIOD-238 and BIOD-250--are combinations of Biodel's technology with the marketed formulation of Humalog.
http://www.nasdaq.com/article/biode...-results-in-study-20130124-00815#.UQGUdifsySo
The biopharmaceutical drug developer's shares were up 26% at $2.96 in early trading.
Biodel, which focuses on diabetes treatments, applies its technology to existing drugs in an effort to improve them. The company's two product formulations--BIOD-238 and BIOD-250--are combinations of Biodel's technology with the marketed formulation of Humalog.
http://www.nasdaq.com/article/biode...-results-in-study-20130124-00815#.UQGUdifsySo